The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson and consumer goods editor/analyst Austin Smith discuss topics across the investing world.
In today's editions, David and Austin discuss Keryx Biopharmaceuticals' recent pipeline success. Keryx investors have suffered recently after the failure of lead drug perifosine in colon cancer; however, a late-stage asset is showing promise and bringing shares back to life. David and Austin catch viewers up on the recent action around the stock and discuss what this trial success means for Keryx, its shareholders, and its potential competitors.
Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report: "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.
Austin Smith has no positions in the stocks mentioned above. David Williamson has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.